An insurance company repeatedly denied a Wisconsin woman coverage for a medication her doctor prescribed to treat her ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for a drug that’s also piqued Johnson & Johnson’s interest.

Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit their main goals.

Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against the relapsing form of the disease, the Swiss drugmaker said on Monday, ...

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, cutting the number of relapses compared to another treatment over nearly ...

Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis. | Contineum Therapeutics’ M1 receptor ...

Shares of US clinical-stage biotech Contineum Therapeutics were down 8.7% at $11.16 in pre-market activity today, after it ...

JACKSON, Miss. (AP) — Federal authorities on Thursday announced indictments against 20 people, including 14 current or former Mississippi Delta law enforcement officers, that allege the officers took ...

A 19-year-old who was diagnosed with a rare form of motor neurone disease (MND) in August has said it is "disgusting" that ...

This article first appeared on GuruFocus. Roche Holding (RHHBF) could be entering a new growth chapter after unveiling strong late-stage trial data for its multiple sclerosis drug fenebrutinib. The ...

A Pierce County woman alleges Rainier Recovery's negligent care contributed to her son's death, exposing a pattern of unqualified staff and inadequate treatment.